What's new in stroke? The top 10 studies of 2009-2011: Part II

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 6, 2011, Pages 200-207

  Hart, Robert G ^a   Oczkowski, Wiesław J ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Atrial fibrillation; Carotid stenting; Clopidogrel; Novel anticoagulants; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; CLOPIDOGREL; DABIGATRAN; PANTOPRAZOLE; QUINIDINE; RIVAROXABAN; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; VERAPAMIL; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DYSPEPSIA; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; LIVER TOXICITY; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STENT; STROKE; TREATMENT OUTCOME;

EID: 79959544824     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1057     Document Type: Review

References (29)

1. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010; 375: 1695-1703.
2. Sandset EC, Bath PMW, Boysen G, et al.; SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomized, placebo-controlled, double-blind trial. Lancet. 2011; 377: 741-750.
3. Dennis M, Sandercock PA, Reid J, et al.; CLOTS Trials Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomized controlled trial. Lancet. 2009; 373: 1958-1965.
4. Molyneux AJ, Kerr RSC, Birks J, et al.; ISAT Collaborators Risk of recurrent subarachnoid haemorrhage, death, dependence and standardized mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. Lancet Neurol. 2009: 8: 427-433.
5. Furlan AJ. CLOSURE I Trial. Abstract presented at the 2010 American Heart Association meeting (Chicago, USA, November). In press.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
7. Connolly SJ, Pogue J, Hart RG, et al.; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360: 2066-2078.
8. Connolly SJ, Eikelboom JW, Joyner C, et al.; AVERROES Steering Committee and Investigators. Effect of apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-817.
9. Brott TG, Hobson RW, Howard G, et al. Stenting vs. endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010; 363: 11-23.
10. Ederle J, Dobson J, Featherstone RL, et al.; International Carotid Stenting Study Investigators. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomized controlled trial. Lancet. 2010: 375: 985-997.
11. Bonati LH, Dobson J, Algra A, et al.; Carotid Stenting Trialists' Collaboration. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet. 2010; 378; 1062-1073.
12. Oczkowski WJ, Hart RG. What's new in stroke? The top 10 studies of 2009-2011: Part I. Pol Arch Med Wewn. In press.
13. Karthikeyan G, Eikelboom JW, Hirsh J. New oral anticoagulants: not quite there yet. Pol Arch Med Wewn. 2009; 119: 53-59.
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010; 363: 1875-1876.
15. Karthikeyan G, Eikelboom JW, Hirsh J. Dabigatran: ready for prime time? Pol Arch Med Wewn. 2010; 120: 137-142.
16. Douketis JD. Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management. Pol Arch Med Wewn. 2011; 121: 73-80.
17. Wallentin L, Yusuf S, Ezekowitz MD, et al.; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376: 975-983.
18. Gage BF. Can we rely on RE-LY? N Engl J Med. 2009; 361: 1200-1202.
19. Wann LS, Curtis AB, Ellenbogen KA, et al.; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). Circulation. 2011; 123; 1140-1150.
20. Connolly S, Pogue J, Hart R, et al.; ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
21. Abraham NS, Hlatky MA, Antman EM, et al.; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus doument on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010; 56: 2051-2066.
22. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost. 2009; 35: 515-524.
23. Lopes BD, Alexander JH, Al-Khatib SM, et al.; ARISTOTLE Investigators. Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010; 159: 331-339.
24. Executive Steering Committee on behalf of the ROCKET AF Study Investigators. Rivaroxaban - Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: the ROCKET AF study. Abstract presented at the 2010 American Heart Association Scientific Sessions, Chicago USA.
25. Davis SM, Donnan GA. Carotid-artery stenting in stroke prevention. N Engl J Med. 2010; 363: 80-82.
26. Bonati LH, Jongen LM, Haller S, et al.; ICSS-MRI study group. New ischemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). Lancet Neurol. 2010; 9: 353-362.
27. Amarenco P, Labreuche J, Mazighi M. Lessons from carotid endarterectomy and stenting trials. Lancet. 2010; 376: 1028-1031.
28. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee Guidelines for management of ischaemic stroke and transient ischemic attack 2008. Cerebrovasc Dis. 2008; 25: 457-507.
29. National Institute of Neurological Disorders and Stroke. Neurological Clinical Alert Angioplasty Combined with Stenting Plus Aggressive Medical Therapy vs. Aggressive Medical Therapy Alone for Intracranial Arterial Stenosis: NINDS Stops Trial Enrollment Due to a Higher Risk of Stroke and Death in the Stented Group. http://members.asnr.org/misc/NINDS-Clinical-Alert.pdf. Accessed April 12, 2011.